Data exclusivity: a new threat to affordable generic medicines

HIV Treat Bull - Vol. 7, No. 7/8, July/August 2006

The following information relates to the decision by the Indian government to amend the Drugs and Cosmetic Act, 1950. This is the act that protected the process a company invented to make a drug, but not the actual drug formulation itself, and which enabled some Indian generic manufacturers to produce chemically equivalent generic medicines at prices affordable to the developing world.

The Indian government are seriously contemplating inserting provisions in the Act, which will provide pharmaceutical companies exclusive rights over pharmaceutical data submitted by them to the Drug Controller of India for marketing approval i.e. data exclusivity.

What is data exclusivity?

• A new type of intellectual property right in the name of data protection, intended to provide exclusive monopoly rights to pharmaceutical companies where patents would not. Unlike what is being portrayed to the people and the media, Data Exclusivity‚ measures imply much more than non-disclosure of test data by the drug regulatory authority to rival pharmaceutical companies.
• Changes the current system of approval for generic medicines.
• How does it impact access to generic drugs: Provides pharmaceutical companies exclusive rights on pharmaceutical data so that they can effectively prevent the drug regulatory authorities (DRA) themselves from relying on test data already in their possession for subsequent approval of generic versions of the medicine.
• Practically, prevents DRAs from registering generic versions of a medicine for a period ranging from 5 to 10 years, unless the generic manufacturer independently carries out its own tests showing the safety and efficacy of the medicine.
• Even when a medicine is not protected by any patent, pharmaceutical companies are assured a minimum period of monopoly because of data exclusivity.
• It is the regulatory authorities that enforce data exclusivity rights. Unlike patents, the rights holder is spared the expense and embarrassment of being seen to enforce their rights in public. Public health agencies reduced to enforcing private commercial rights!

What is the current practice for approval of generic drugs?

As of now there are no data exclusivity provisions in Indian law. According to current practice in India, generic manufacturers have to apply for marketing approval of the generic version of a medicine to the DCGI. They are off-course required to provide bio-equivalence studies to prove that their generic version of the medicine is the therapeutic equivalent to the original and do not have to again submit test data regarding safety and efficacy which is already with the DCGI. For this the DCGI is entitled to rely on test data submitted by the pharmaceutical company who first sought marketing approval for the medicine.

Why are public interest groups concerned?

• Data exclusivity‚ measures have the effect of limiting generic competition. Generic production of drugs has been one of the most important, reliable, and powerful forces to reduce drug prices systematically in India and other developing regions, making essential, life-saving medicines such as antiretrovirals (ARVs) for the treatment of HIV/AIDS more affordable for individuals and the health systems that serve them.
• If such data exclusivity provisions are introduced in India the Drug Controller of India (DCGI) will be barred from relying on test data, which is already in its possession in granting marketing approval to generic medicines. Instead it will be forced to ask the Indian generic manufacturer to carry out its own clinical trials showing efficacy and safety of the medicine. Theoretically data exclusivity provisions do not legally prevent generic manufacturers from generating their own test data for marketing approval. However in reality the financial resources and the time needed for conducting clinical trials for generating test data already available with the Drug Controller creates a market barrier that is difficult for generic manufacturers to overcome and delays the introduction of the generic drug by a number of years.
• Data exclusivity measures in other countries is already preventing drug regulatory authorities from granting approval to generic medicines up to five to ten years, seriously delaying access to affordable generic versions of medicines. In Guatemala in February 2004, Atazanavir a drug used in HIV treatment (priced at US$ 10, 000 per person per year) received data exclusivity protection for five years under the law passed by the government. However a more affordable generic version of Atazanavir cannot enter the Guatemalan market until 2009 as drug regulatory authorities have to provide data exclusivity protection to test data related to Atazanavir. As a consequence drug Regulatory authorities in Guatemala are themselves barred from relying on it to approve of subsequent generic versions.
• Coupled with the new patent law this can easily result in an absolute monopoly regime in pharmaceuticals, seriously affecting the manufacture and availability of affordable generic drugs. Can also seriously limit the ability of the government to make use of safeguards in their patent laws to protect public health.
• Unnecessary and possible human injury associated with duplicative testing

What can organisations and individuals do?

The government is considering amendments to the Drugs and Cosmetics Act as it is under pressure from US, and multinational pharmaceutical companies to amend the Act to include data exclusivity protection provisions (see pg 103 of 2005 PhRMA “Special 301” Submission to United States Trade Representative).

• Write to the government of India to ask for more information on the issue and also to convey your concern on its possible decision on amending the Drugs and Cosmetic Act to include such provisions.
• Brief the parliamentarians and policy makers on the implications of data exclusivity
• Mobilise public opinion against such move

Source: Leena Menghaney, Campaign for Access to Essential Medicines, Medecins Sans Frontieres, Holland (in India)

2008-03-10
IB060707-25

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.